Rafarma Pharmaceuticals Stock Price To Earnings To Growth
| RAFA Stock | USD 0.09 0 4.40% |
Rafarma Pharmaceuticals fundamentals help investors to digest information that contributes to Rafarma Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Rafarma Pink Sheet. The fundamental analysis module provides a way to measure Rafarma Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rafarma Pharmaceuticals pink sheet.
Rafarma |
Rafarma Pharmaceuticals Company Price To Earnings To Growth Analysis
Rafarma Pharmaceuticals' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Rafarma Pharmaceuticals has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Rafarma Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rafarma Pharmaceuticals' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Rafarma Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rafarma Pharmaceuticals by comparing valuation metrics of similar companies.Rafarma Pharmaceuticals is currently under evaluation in price to earnings to growth category among its peers.
Rafarma Fundamentals
| Return On Equity | -7.0E-4 | |||
| Return On Asset | -4.0E-4 | |||
| Profit Margin | (0.88) % | |||
| Operating Margin | (0.81) % | |||
| Current Valuation | 7.89 M | |||
| Price To Earning | (1.29) X | |||
| Price To Sales | 857.77 X | |||
| Net Income | (14.85 K) | |||
| Book Value Per Share | 40.49 X | |||
| Cash Flow From Operations | (1 K) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | -0.39 | |||
| Market Capitalization | 110.29 M | |||
| Total Asset | 460.33 M | |||
| Retained Earnings | (2.38 M) | |||
| Current Liabilities | 292 K | |||
| Net Asset | 460.33 M |
About Rafarma Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rafarma Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rafarma Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rafarma Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Rafarma Pink Sheet
Rafarma Pharmaceuticals financial ratios help investors to determine whether Rafarma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rafarma with respect to the benefits of owning Rafarma Pharmaceuticals security.